Chronic lymphocytic leukaemia (CLL)

Active Ingredient: Ibrutinib

Indication for Ibrutinib

Population group: only adults (18 years old or older)

Ibrutinib as a single agent or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).

Ibrutinib as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.

For this indication, competent medicine agencies globally authorize below treatments:

420 mg once daily

Route of admnistration

Oral

Defined daily dose

420 - 420 mg

Dosage regimen

From 420 To 420 mg once every day

Detailed description

The recommended dose for the treatment of CLL, either as a single agent or in combination, is 420 mg once daily.

Treatment should continue until disease progression or no longer tolerated by the patient.

When administering ibrutinib in combination with anti-CD20 therapies, it is recommended to administer ibrutinib prior to rituximab or obinutuzumab when given on the same day.

Active ingredient

Ibrutinib

Ibrutinib is a potent, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). BTK, a member of the Tec kinase family, is an important signalling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. Preclinical studies have shown that ibrutinib effectively inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro.

Read more about Ibrutinib

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.